Clinical trials in rare diseases are more challenging than clinical trials in more frequent diseases for many factors such as the trial design, the number of patient populations available for recruitment, regulatory support, etc. Applying a perfect strategy for clinical development in rare diseases may help overcome these challenges and accelerate the drug development process […]

Read More →

China is the largest clinical trial market in Asia and the 5th largest in the world. In recent years there was a remarkable increase in Phase I-III clinical trials. Understandably, there must be something significant happening, which brought this change. The recent changes in policies and regulations in China have brought a lot of cheer from […]

Read More →